What is PTC Therapeutics Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. PTC Therapeutics's interest expense for the
three
months ended in Mar. 2025 was $ -34 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2025 was $-160 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. PTC Therapeutics's Operating Income for the
three
months ended in Mar. 2025 was $ 970 Mil. PTC Therapeutics's Interest Expense for the
three
months ended in Mar. 2025 was $ -34 Mil.
PTC Therapeutics's Interest Coverage for the quarter that ended in Mar. 2025 was 28.44.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
PTC Therapeutics Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-160 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PTC Therapeutics (NAS:PTCT) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
PTC Therapeutics's Interest Expense for the
three
months ended in Mar. 2025 was $-34 Mil. Its
Operating Income
for the
three
months ended in Mar. 2025 was $970 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2025 was $373 Mil.
PTC Therapeutics's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
PTC Therapeutics Business Description
Traded in Other Exchanges
Address
500 Warren Corporate Center Drive, Warren, NJ, USA, 07059
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Executives
| Mark Elliott Boulding |
officer: Exec. VP and CLO |
C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
| Matthew B. Klein |
officer: Chief Development Officer |
C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
| Lee Scott Golden |
officer: Chief Medical Officer |
17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152 |
| Eric Pauwels |
officer: Chief Business Officer |
550 HILLS DRIVE, BEDMINSTER NJ 07921 |
| Stephanie Okey |
director |
C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109 |
| Allan Steven Jacobson |
director |
PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
| Neil Gregory Almstead |
officer: EVP Research Pharma Ops & Tech |
C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
| Pierre Gravier |
officer: CHIEF FINANCIAL OFFICER |
C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
| Christine Marie Utter |
officer: Principal Financial Officer |
C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
| Jerome B Zeldis |
director |
8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258 |
| Michael Schmertzler |
director |
110 WASHINGTON STREET, SUITE 1300, CONSHOHOCKEN PA 19428 |
| Alethia Young |
director |
C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080 |
| Bell William F. Jr. |
director |
C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
| Emma Reeve |
director |
C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451 |
| David P Southwell |
director |
C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421 |
PTC Therapeutics Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PTCT has been successfully added to your 